Top

Published in:

Open Access 01-10-2016 | Research Article

Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin

Authors: Stefanie M. A. Willekens, Lieke Joosten, Otto C. Boerman, Alexander Balhuizen, Decio L. Eizirik, Martin Gotthardt, Maarten Brom

Published in: Molecular Imaging and Biology | Issue 5/2016

Abstract

Purpose

Noninvasive beta cell mass (BCM) quantification is a crucial tool to understand diabetes development and progression. [¹¹¹In]exendin is a promising agent for in vivo beta cell imaging, but tracer testing has been hampered by the lack of well-defined rodent models.

Procedures

Biodistribution and pancreatic uptake of [¹¹¹In]exendin were compared in rats and mice. In selected models, the amount of [¹¹¹In]exendin accumulation in the pancreas and other organs was determined using a model of alloxan-induced beta cell loss. GLP-1R expression levels were analyzed by RT-PCR and immunohistochemistry.

Results

Namely Brown Norway rats showed beta-cell-specific tracer accumulation and favorable pancreas-to-background ratios for noninvasive BCM determination. Mice displayed receptor-mediated [¹¹¹In]exendin uptake in endocrine and exocrine pancreas, in spite of very low GLP-1R expression in exocrine tissue.

Conclusions

Rats display better characteristics for in vivo BCM determination than mice and are suggested as a more adequate model for humans.

Available only for authorised users

Lohr M, Kloppel G (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30:757–762CrossRefPubMed

Butler AE, Janson J, Bonner-Weir S et al (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed

Steele C, Hagopian WA, Gitelman S et al (2004) Insulin secretion in type 1 diabetes. Diabetes 53:426–433CrossRefPubMed

Cnop M, Welsh N, Jonas JC et al (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2):S97–S107CrossRefPubMed

Weir GC, Bonner-Weir S (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16–S21CrossRef

Ritzel RA, Butler AE, Rizza RA et al (2006) Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718CrossRefPubMed

Yang L, Ji W, Xue Y, Chen L (2013) Imaging beta-cell mass and function in situ and in vivo. J Mol Med 91:929–938CrossRefPubMed

Eriksson AU, Svensson C, Hornblad A et al (2013) Near infrared optical projection tomography for assessments of beta-cell mass distribution in diabetes research. J Vis Exp 71:e50238

Virostko J, Radhika A, Poffenberger G et al (2013) Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model. PLoS ONE 8:e57784

10.

Stasiuk GJ, Minuzzi F, Sae-Heng M et al (2015) Dual-modal magnetic resonance/fluorescent zinc probes for pancreatic beta-cell mass imaging. Chemistry 21:5023–5033CrossRefPubMedPubMedCentral

11.

Vinet L, Lamprianou S, Babic A et al (2015) Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice. Diabetologia 58:304–312CrossRef

12.

Antkowiak PF, Stevens BK, Nunemaker CS et al (2013) Manganese-enhanced magnetic resonance imaging detects declining pancreatic beta-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes. Diabetes 62:44–48CrossRefPubMed

13.

Pattou F, Kerr-Conte J, Wild D (2010) GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. New Engl J Med 363:1289–1290CrossRefPubMed

14.

Brom M, Woliner-van der Weg W, Joosten L et al (2014) Non-invasive quantification of the beta cell mass by SPECT with In-labelled exendin. Diabetologia 57(5):950–959

15.

Eriksson O, Espes D, Selvaraju RK et al (2014) Positron emission tomography ligand [¹¹C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. Diabetes 63:3428–3437CrossRefPubMed

16.

Aaen K, Rygaard J, Josefsen K et al (1990) Dependence of antigen expression on functional state of beta-cells. Diabetes 39:697–701CrossRefPubMed

17.

Malaisse WJ, Damhaut P, Malaisse-Lagae F et al (2000) Fate of 2-deoxy-2-[¹⁸F]fluoro-D-glucose in control and diabetic rats. Int J Mol Med 5:525–532PubMed

18.

Eriksson O, Selvaraju RK, Johansson L et al (2014) Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med 55:460–465CrossRefPubMed

19.

Simpson NR, Souza F, Witkowski P et al (2006) Visualizing pancreatic beta-cell mass with [¹¹C]DTBZ. Nucl Med Biol 33:855–864CrossRefPubMedPubMedCentral

20.

Brom M, Joosten L, Frielink C et al (2015) (111)In-exendin uptake in the pancreas correlates with the beta-cell mass and not with the alpha-cell mass. Diabetes 64:1324–1328CrossRefPubMed

21.

Kung MP, Hou C, Lieberman BP et al (2008) In vivo imaging of beta-cell mass in rats using ¹⁸F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 49:1171–1176CrossRefPubMed

22.

Mathijs I, Xavier C, Peleman C et al (2015) A standardized method for in vivo mouse pancreas imaging and semiquantitative beta cell mass measurement by dual isotope SPECT. Mol Imaging Biol 17:58–66CrossRefPubMed

23.

Mikkola K, Yim CB, Fagerholm V et al (2014) 64Cu- and 68Ga-labelled [Nle(14), Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 16:255–263CrossRefPubMed

24.

Reiner T, Thurber G, Gaglia J et al (2011) Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A 108:12815–12820CrossRefPubMedPubMedCentral

25.

Villate O, Turatsinze JV, Mascali LG et al (2014) Nova1 is a master regulator of alternative splicing in pancreatic beta cells. Nucleic Acids Res 42:11818–11830CrossRefPubMedPubMedCentral

26.

Fukaya M, Tamura Y, Chiba Y et al (2013) Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced beta-cell damage and diabetes in mice. Biochem Biophys Res Commun 442:92–98CrossRefPubMedPubMedCentral

27.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25:402–408CrossRefPubMed

28.

Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC (2012) Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging 7:160–166CrossRefPubMedPubMedCentral

29.

Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ (2004) Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharmac Des 10:2951–2963CrossRef

30.

Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28–47CrossRefPubMed

31.

Nalin L, Selvaraju RK, Velikyan I et al (2014) Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs. Eur J Nucl Med Mol Imaging 41:1800–1810CrossRefPubMed

Title: Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin
Authors: Stefanie M. A. Willekens
Lieke Joosten
Otto C. Boerman
Alexander Balhuizen
Decio L. Eizirik
Martin Gotthardt
Maarten Brom
Publication date: 01-10-2016
Publisher: Springer US
Published in: Molecular Imaging and Biology / Issue 5/2016
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-016-0936-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2016

Comparative Study of Tumor Targeting and Biodistribution of pH (Low) Insertion Peptides (pHLIP® Peptides) Conjugated with Different Fluorescent Dyes

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany

Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [18F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers

[18F]FDG PET Neuroimaging Predicts Pentylenetetrazole (PTZ) Kindling Outcome in Rats

Generation and Application of Male Mice with Specific Expression of Green Fluorescent Protein in Germ Cells

Detection of Lymph Node Metastases with SERRS Nanoparticles